INNOVENT BIO (01801.HK)  +0.850 (+1.176%)    Short selling $121.31M; Ratio 6.982%   presented multiple datat the 2025 ASCO Annual Meeting, with particular attention on the PD-1/IL-2α-bias bispecific antibody fusion protein IBI363, CICC published a research report saying.

The broker believed that the newly disclosed data for colorectal cancer patients exceeded expectations, and suggested that IBI363 has the potential to become a blockbuster in this field. Furthermore, IBI363 continued to demonstrate leading competitiveness in IO-treated lung cancer.

Related NewsBOCI Elevates INNOVENT BIO (01801.HK) TP to $82, Keeps Rating at Buy
CICC maintained its 2025/ 2026 net profit forecasts for INNOVENT BIO at RMB472 million/ RMB1.3 billion, and kept rating at Outperform. Considering the higher-than-expected colorectal cancer data for IBI363, the broker raised its target price by 4.5% to $69.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)